New search Hide text from Guidelines
N NERVOUS SYSTEMN04 ANTI-PARKINSON DRUGS
This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.
| The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease. No separate DDDs are established for oral depot formulations. |
N04B DOPAMINERGIC AGENTS
N04BA Dopa and dopa derivatives
Combinations with decarboxylase inhibitors and other dopaminergic agents are classified here.
| The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index. |
| ATC code | Name | DDD | U | Adm.R | Note |
| N04BA01 | levodopa | 3.5 | g | O | |
| N04BA02 | levodopa and decarboxylase inhibitor | 0.6 | g | O | Refers to levodopa |
| N04BA03 | levodopa, decarboxylase inhibitor and COMT inhibitor | 0.45 | g | O | Refers to levodopa |
| N04BA04 | melevodopa | ||||
| N04BA05 | melevodopa and decarboxylase inhibitor | ||||
| N04BA06 | etilevodopa and decarboxylase inhibitor | ||||
| N04BA07 | foslevodopa and decarboxylase inhibitor |
Last updated: 2024-01-26